Procept BioRobotics Faces Revenue Target Challenges Amid Pricing Changes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy PRCT?
Source: PRnewswire
- Revenue Target Miss: Procept BioRobotics guided for $325.5 million in 2025 revenue but fell short with $308.1 million, a $17.4 million shortfall that caused shares to drop over 15% in a single session, indicating market concerns about future growth.
- Pricing Strategy Shift: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, directly reducing average selling prices of its core products to approximately $3,200, a change that was not quantified in revenue guidance and may impact future sales performance.
- Profitability Commitment: Despite CFO Kevin Waters reaffirming revenue targets, CEO Larry Wood stated that strategic investments would not impede profitability progress; however, market confidence in the company's ability to meet these targets has significantly weakened, reflecting skepticism about management's commitments.
- Uncertain Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, further exacerbating investor anxiety and highlighting the significant challenges the company faces in achieving its growth objectives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 26.360
Low
38.00
Averages
51.75
High
65.00
Current: 26.360
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Procept BioRobotics Lowers 2025 Revenue Guidance
- Revenue Growth Expectations: Procept BioRobotics guided for $325.5 million in 2025 revenue, projecting a 45% increase, yet reported only $308.1 million, falling short by $17.4 million, which caused shares to drop over 15% in a single day.
- Pricing Strategy Adjustment: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, resulting in a decrease in average selling prices to approximately $3,200 for its core product line, although the CFO stated this would not impede profitability progress.
- Dismal Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, indicating pressure in market competition and uncertainty in profitability, which could undermine investor confidence.
- Shareholder Rights Protection: Following the stock decline, shareholders of Procept BioRobotics are encouraged to submit their information to discuss legal rights, indicating potential litigation risks for the company that may further impact its market reputation.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Participants: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Collaborative Advantages: By collaborating with Mayo Clinic and Sutter Health, Sonder Capital can leverage insights from frontline care delivery to help portfolio companies ensure that innovations translate directly into better patient care, thereby strengthening its market competitiveness.
- Revolution in Medical Robotics: Medical robotics has already transformed possibilities in the operating room, and the integration of AI is expected to further accelerate automation and performance improvements across care pathways, benefiting patients, clinicians, and health systems globally.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Investors: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Technological Innovation and Impact: The introduction of medical robotics has already transformed operating room procedures, and the addition of AI is set to unlock new levels of performance and automation across care pathways, accelerating a revolution in healthcare systems worldwide that will benefit patients and clinicians alike.
- Team Background and Success Stories: Sonder Capital's team consists of seasoned investors and innovators who have successfully supported numerous companies that have transformed the healthcare industry, including Intuitive Surgical and Shockwave Medical, showcasing their deep expertise in healthcare investment.
See More
Procept BioRobotics Faces Revenue Target Challenges Amid Pricing Changes
- Revenue Target Miss: Procept BioRobotics guided for $325.5 million in 2025 revenue but fell short with $308.1 million, a $17.4 million shortfall that caused shares to drop over 15% in a single session, indicating market concerns about future growth.
- Pricing Strategy Shift: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, directly reducing average selling prices of its core products to approximately $3,200, a change that was not quantified in revenue guidance and may impact future sales performance.
- Profitability Commitment: Despite CFO Kevin Waters reaffirming revenue targets, CEO Larry Wood stated that strategic investments would not impede profitability progress; however, market confidence in the company's ability to meet these targets has significantly weakened, reflecting skepticism about management's commitments.
- Uncertain Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, further exacerbating investor anxiety and highlighting the significant challenges the company faces in achieving its growth objectives.
See More
Procept BioRobotics Faces Revenue Target Challenges
- Revenue Target Set: Procept BioRobotics guided for $325.5 million in FY 2025 revenue, representing a 45% growth, but actual revenue fell to $308.1 million, resulting in a more than 15% drop in stock price in a single session.
- Pricing Strategy Change: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, directly reducing average selling prices on its core product line, despite the CFO stating that prices would be maintained around $3,200.
- Profitability Commitment: CEO Larry Wood emphasized that strategic investments are not expected to impede the company's progress toward profitability, reflecting management's confidence in future earnings potential.
- Dismal Future Outlook: Upon releasing Q4 2025 results, the company provided FY 2026 revenue guidance of $410 million to $430 million, which fell below analyst consensus, exacerbating market concerns regarding its growth prospects.
See More
Pomerantz Investigates PROCEPT BioRobotics for Securities Fraud
- Disappointing Financial Results: PROCEPT BioRobotics reported fourth-quarter results on February 25, 2026, revealing revenues that fell significantly short of analyst expectations, prompting a downward revision of its full-year 2026 revenue guidance from $410-$430 million to $390-$410 million, indicating serious operational challenges.
- Significant Stock Decline: Following the earnings report, PROCEPT's stock price plummeted by $4.21, or 15.12%, closing at $23.63 per share on February 26, 2026, reflecting market concerns regarding the company's future outlook.
- Investigation Launched: Pomerantz LLP is investigating whether PROCEPT and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, which suggests potential legal risks that could further impact the company.
- Impact of Business Restructuring: The company's mention of a realignment of its commercial organization and the elimination of bulk purchasing discounts for handpieces may lead to customer attrition and a decline in market share, exacerbating its challenges in the competitive medical device market.
See More
Procept BioRobotics Lowers 2025 Revenue Guidance
- Revenue Growth Expectations: Procept BioRobotics guided for $325.5 million in 2025 revenue, projecting a 45% increase, yet reported only $308.1 million, falling short by $17.4 million, which caused shares to drop over 15% in a single day.
- Pricing Strategy Adjustment: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, resulting in a decrease in average selling prices to approximately $3,200 for its core product line, although the CFO stated this would not impede profitability progress.
- Dismal Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, indicating pressure in market competition and uncertainty in profitability, which could undermine investor confidence.
- Shareholder Rights Protection: Following the stock decline, shareholders of Procept BioRobotics are encouraged to submit their information to discuss legal rights, indicating potential litigation risks for the company that may further impact its market reputation.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Participants: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Collaborative Advantages: By collaborating with Mayo Clinic and Sutter Health, Sonder Capital can leverage insights from frontline care delivery to help portfolio companies ensure that innovations translate directly into better patient care, thereby strengthening its market competitiveness.
- Revolution in Medical Robotics: Medical robotics has already transformed possibilities in the operating room, and the integration of AI is expected to further accelerate automation and performance improvements across care pathways, benefiting patients, clinicians, and health systems globally.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Investors: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Technological Innovation and Impact: The introduction of medical robotics has already transformed operating room procedures, and the addition of AI is set to unlock new levels of performance and automation across care pathways, accelerating a revolution in healthcare systems worldwide that will benefit patients and clinicians alike.
- Team Background and Success Stories: Sonder Capital's team consists of seasoned investors and innovators who have successfully supported numerous companies that have transformed the healthcare industry, including Intuitive Surgical and Shockwave Medical, showcasing their deep expertise in healthcare investment.
See More
Procept BioRobotics Faces Revenue Target Challenges Amid Pricing Changes
- Revenue Target Miss: Procept BioRobotics guided for $325.5 million in 2025 revenue but fell short with $308.1 million, a $17.4 million shortfall that caused shares to drop over 15% in a single session, indicating market concerns about future growth.
- Pricing Strategy Shift: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, directly reducing average selling prices of its core products to approximately $3,200, a change that was not quantified in revenue guidance and may impact future sales performance.
- Profitability Commitment: Despite CFO Kevin Waters reaffirming revenue targets, CEO Larry Wood stated that strategic investments would not impede profitability progress; however, market confidence in the company's ability to meet these targets has significantly weakened, reflecting skepticism about management's commitments.
- Uncertain Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, further exacerbating investor anxiety and highlighting the significant challenges the company faces in achieving its growth objectives.
See More
Procept BioRobotics Faces Revenue Target Challenges
- Revenue Target Set: Procept BioRobotics guided for $325.5 million in FY 2025 revenue, representing a 45% growth, but actual revenue fell to $308.1 million, resulting in a more than 15% drop in stock price in a single session.
- Pricing Strategy Change: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, directly reducing average selling prices on its core product line, despite the CFO stating that prices would be maintained around $3,200.
- Profitability Commitment: CEO Larry Wood emphasized that strategic investments are not expected to impede the company's progress toward profitability, reflecting management's confidence in future earnings potential.
- Dismal Future Outlook: Upon releasing Q4 2025 results, the company provided FY 2026 revenue guidance of $410 million to $430 million, which fell below analyst consensus, exacerbating market concerns regarding its growth prospects.
See More
Pomerantz Investigates PROCEPT BioRobotics for Securities Fraud
- Disappointing Financial Results: PROCEPT BioRobotics reported fourth-quarter results on February 25, 2026, revealing revenues that fell significantly short of analyst expectations, prompting a downward revision of its full-year 2026 revenue guidance from $410-$430 million to $390-$410 million, indicating serious operational challenges.
- Significant Stock Decline: Following the earnings report, PROCEPT's stock price plummeted by $4.21, or 15.12%, closing at $23.63 per share on February 26, 2026, reflecting market concerns regarding the company's future outlook.
- Investigation Launched: Pomerantz LLP is investigating whether PROCEPT and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, which suggests potential legal risks that could further impact the company.
- Impact of Business Restructuring: The company's mention of a realignment of its commercial organization and the elimination of bulk purchasing discounts for handpieces may lead to customer attrition and a decline in market share, exacerbating its challenges in the competitive medical device market.
See More
